Company intelligence / Profile preview

Aviko Radiopharmaceuticals

New York City, New York, United Statesavikofoodservice.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aviko is developing a pipeline of novel boron medicines designed to enable BNCT, a precision therapy that selectively destroys cancer cells while sparing healthy tissue. The company is building partnerships to establish the first BNCT treatment centers in the U.S., leveraging recent advances in neutron delivery technology and medicinal chemistry. Clinical results from Japan show efficacy for locally recurrent unresectable head and neck cancer; further studies are underway globally

Therapeutic areas: Oncology
Modalities: Boron-based small molecules for Boron Neutron Capture Therapy (BNCT)
Industry: Biotech

Partnerships

Neutron Therapeutics (neutron delivery systems for BNCT)Leo Cancer Care (upright patient positioning systems integrated into therapy platform)Academic medical centers in the U.S., EU, Asia for clinical collaborations

Beyond the preview

Go deeper on Aviko Radiopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aviko Radiopharmaceuticals.

Explore the full profile